Home › Funds › PSP Research LLC › CRNX

PSP Research LLC position in CRNX

CRINETICS PHARMACEUTICALS IN

PSP Research LLC reported holding 11,000 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$412K, representing 0.22% of its reported portfolio and ranking #32 among its reported holdings. PSP Research LLC has disclosed CRNX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)11.00K sh
Reported value held$411.62K
Portfolio Weight0.22%
First reportedQ4 2025
Last changeNew

How PSP Research LLC's CRNX position evolved

PSP Research LLC first disclosed a stake in CRNX in Q4 2025 at 11,316 shares (US$527K). Across 3 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 11,000 shares valued at US$412K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 11.32K $526.76K New
Q1 2026 11.00K $399.52K Reduce
Q2 2026 11.00K $411.62K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 38 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →